Rules of the Game: Sizing Up the Bottom Line
If you are holding individual stocks -- and that's certainly not required of every investor, since ETFs offer a perfectly acceptable way of spreading risk -- it's wise to incorporate earnings estimates into your analysis.
For an example, one large-cap that's expected to grow earnings at a double-digit rate this year is Valeant Pharmaceuticals (VRX), which makes treatments for nervous-system and cardiovascular disorders. Earnings are due Feb. 28 before the open -- and, for the full year, Valeant is expected to deliver income of $4.50 per share, up 54% over 2011. Analysts have pegged 2013 earnings at $5.62 per share, which would mark another 25% gain from last year's expectations....416 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.